474 related articles for article (PubMed ID: 34868984)
1. Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives.
Peng Y; Mei W; Ma K; Zeng C
Front Oncol; 2021; 11():763790. PubMed ID: 34868984
[TBL] [Abstract][Full Text] [Related]
2. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review).
Chen H; Zhou Q
Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271
[TBL] [Abstract][Full Text] [Related]
3. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay.
Hashimoto T; Nakamura Y; Oki E; Kobayashi S; Yuda J; Shibuki T; Bando H; Yoshino T
Int J Clin Oncol; 2024 May; 29(5):495-511. PubMed ID: 38551727
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review.
Zhu L; Xu R; Yang L; Shi W; Zhang Y; Liu J; Li X; Zhou J; Bing P
Front Genet; 2023; 14():1172108. PubMed ID: 37636270
[TBL] [Abstract][Full Text] [Related]
5. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
6. Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease.
Moding EJ; Nabet BY; Alizadeh AA; Diehn M
Cancer Discov; 2021 Dec; 11(12):2968-2986. PubMed ID: 34785539
[TBL] [Abstract][Full Text] [Related]
7. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
Arisi MF; Dotan E; Fernandez SV
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
[TBL] [Abstract][Full Text] [Related]
8. Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors.
Larribère L; Martens UM
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830853
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer.
Fang X; Yu S; Jiang Y; Xiang Y; Lu K
Front Oncol; 2022; 12():1027664. PubMed ID: 36387176
[TBL] [Abstract][Full Text] [Related]
10. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).
Chin RI; Chen K; Usmani A; Chua C; Harris PK; Binkley MS; Azad TD; Dudley JC; Chaudhuri AA
Mol Diagn Ther; 2019 Jun; 23(3):311-331. PubMed ID: 30941670
[TBL] [Abstract][Full Text] [Related]
11. Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors.
Kasi PM; Fehringer G; Taniguchi H; Starling N; Nakamura Y; Kotani D; Powles T; Li BT; Pusztai L; Aushev VN; Kalashnikova E; Sharma S; Malhotra M; Demko ZP; Aleshin A; Rodriguez A; Billings PR; Grothey A; Taieb J; Cunningham D; Yoshino T; Kopetz S
JCO Precis Oncol; 2022 Mar; 6():e2100181. PubMed ID: 35263168
[TBL] [Abstract][Full Text] [Related]
12. Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions.
Chae YK; Oh MS
J Thorac Oncol; 2019 Jan; 14(1):16-24. PubMed ID: 30296486
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.
Zhong R; Gao R; Fu W; Li C; Huo Z; Gao Y; Lu Y; Li F; Ge F; Tu H; You Z; He J; Liang W
BMC Med; 2023 May; 21(1):180. PubMed ID: 37173789
[TBL] [Abstract][Full Text] [Related]
14. Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC).
Chakrabarti S; Kasi AK; Parikh AR; Mahipal A
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804850
[TBL] [Abstract][Full Text] [Related]
15. The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review.
Chakrabarti S; Xie H; Urrutia R; Mahipal A
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33003583
[TBL] [Abstract][Full Text] [Related]
16. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
17. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.
Eckhoff AM; Kanu E; Fletcher A; Bao M; Aushev VN; Spickard E; Nussbaum DP; Allen PJ
Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407
[TBL] [Abstract][Full Text] [Related]
18. Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges.
Wen X; Coradduzza D; Shen J; Scanu AM; Muroni MR; Massidda M; Rallo V; Carru C; Angius A; De Miglio MR
Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893604
[TBL] [Abstract][Full Text] [Related]
19. Liquid Biopsies for Monitoring Medulloblastoma: Circulating Tumor DNA as a Biomarker for Disease Progression and Treatment Response.
Buccilli B; Rodriguez Molina MA; Redrovan Palomeque DP; Herrera Sabán CA; C Caliwag FM; Contreras Flores CJS; Abeysiriwardana CWJ; Diarte E; Arruarana VS; Calderon Martinez E
Cureus; 2024 Jan; 16(1):e51712. PubMed ID: 38313884
[TBL] [Abstract][Full Text] [Related]
20. Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices.
Malla M; Loree JM; Kasi PM; Parikh AR
J Clin Oncol; 2022 Aug; 40(24):2846-2857. PubMed ID: 35839443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]